Switch theme
Sign up to access all valuation multiples
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
2007
23
LTM Revenue $3.4M
Last FY EBITDA -$41.8M
$8.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Citius Pharmaceuticals has a last 12-month revenue (LTM) of $3.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Citius Pharmaceuticals achieved revenue of n/a and an EBITDA of -$41.8M.
Citius Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Citius Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$41.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$35.9M | XXX | -$42.0M | XXX | XXX | XXX |
| EBIT Margin | -1055% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$43.1M | XXX | -$39.1M | XXX | XXX | XXX |
| Net Margin | -1264% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Citius Pharmaceuticals's stock price is $1.
Citius Pharmaceuticals has current market cap of $7.1M, and EV of $8.0M.
See Citius Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.0M | $7.1M | XXX | XXX | XXX | XXX | $-3.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Citius Pharmaceuticals has market cap of $7.1M and EV of $8.0M.
Citius Pharmaceuticals's trades at n/a EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Citius Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Citius Pharmaceuticals has a P/E ratio of -0.2x.
See valuation multiples for Citius Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.1M | XXX | $7.1M | XXX | XXX | XXX |
| EV (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCitius Pharmaceuticals's last 12 month revenue growth is 1149%
Citius Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Citius Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Citius Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Citius Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1149% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Citius Pharmaceuticals acquired XXX companies to date.
Last acquisition by Citius Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Citius Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Citius Pharmaceuticals founded? | Citius Pharmaceuticals was founded in 2007. |
| Where is Citius Pharmaceuticals headquartered? | Citius Pharmaceuticals is headquartered in United States of America. |
| How many employees does Citius Pharmaceuticals have? | As of today, Citius Pharmaceuticals has 23 employees. |
| Who is the CEO of Citius Pharmaceuticals? | Citius Pharmaceuticals's CEO is Mr. Leonard L. Mazur. |
| Is Citius Pharmaceuticals publicy listed? | Yes, Citius Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Citius Pharmaceuticals? | Citius Pharmaceuticals trades under CTXR ticker. |
| When did Citius Pharmaceuticals go public? | Citius Pharmaceuticals went public in 2011. |
| Who are competitors of Citius Pharmaceuticals? | Similar companies to Citius Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Citius Pharmaceuticals? | Citius Pharmaceuticals's current market cap is $7.1M |
| What is the current revenue of Citius Pharmaceuticals? | Citius Pharmaceuticals's last 12 months revenue is $3.4M. |
| What is the current revenue growth of Citius Pharmaceuticals? | Citius Pharmaceuticals revenue growth (NTM/LTM) is 1149%. |
| What is the current EV/Revenue multiple of Citius Pharmaceuticals? | Current revenue multiple of Citius Pharmaceuticals is 2.3x. |
| Is Citius Pharmaceuticals profitable? | Yes, Citius Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
